123947-65-9

Upstream product

• 2033-89-8 3,4-dimethoxyphenol 
• 123947-72-8 7,8-dimethoxy-2,3-dihydro-1-benzoxepin-4-carboxylic acid 
• 1026461-42-6 5-Hydroxy-7,8-dimethoxy-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid 
• 123947-85-3 methyl 7,8-dimethoxy-5-oxo-2,3,4,5-tetrahydro-1-benzoxepin-4-carboxylate 
• 123947-83-1 4-(3,4-dimethoxyphenoxy)butyric acid 
• 123947-84-2 7,8-dimethoxy-2,3,4,5-tetrahydro-1-benzoxepin-5-one 
• 964-65-8 piperazin-1-yl-(3,4,5,trimethoxy-phenyl)-methanone 
• 1026100-06-0 7,8-dimethoxy-2,3-dihydro-1-benzoxepine-4-carbonyl chloride 

Relevant academic research and scientific papers

Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives

During the screening of novel platelet-activating factor (PAF) antagonists, we found that 1-(6-methoxy-3,4-dihydro-2-naphthoyl)-4-(3,4,5- trimethoxybenzyl)piperazine and its 4-(3,4,5-trimethoxybenzoyl)piperazine derivatives (1b, 2b) exerted in vitro and i

PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof

Platelet Activating Factor (PAF) antagonists which comprises the compounds of the formula (I): wherein A is an optionally substituted phenyl or an optionally substituted heterocyclic group; X is methylene group, carbonyl group or thiocarbonyl group; R1, R2 and R3 are independently a lower alkyl group, and their salts are excellent in absorption from the intestinal canal. Among the compounds of the formula (I), those wherein A is an optionally substituted 2,3-dihydro-1-benzoxepin-4--yl group are novel compounds and exhibit excellent PAF antagonism.

PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof

Platelet Activating Factor (PAF) antagonists which comprise the compounds of the formula (I): STR1 wherein A is an optionally substituted phenyl or an optionally substituted heterocyclic group; X is methylene group, carbonyl group or thiocarbonyl group; R1, R2 and R3 are independently a lower alkyl group, and their salts are excellent in absorption from the intestinal canal. Among the compounds of the formula (I), those wherein A is an optionally substituted 2,3-dihydro-1-benzoxepin-4-yl group are novel compounds and exhibit excellent PAF antagonism.